Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Stymulacja nerwu błędnego w umiarkowanym i ciężkim reumatoidalnym zapaleniu stawów (RESET-RA)

13 listopada 2026 zaktualizowane przez: SetPoint Medical Corporation

Stymulacja nerwu błędnego za pomocą systemu SetPoint w leczeniu reumatoidalnego zapalenia stawów o nasileniu umiarkowanym do ciężkiego: badanie RESET-RA

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.

Przegląd badań

Szczegółowy opis

The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter pivotal study enrolling up to 250 subjects at up to 45 study centers across the U.S. The study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA) who have had an inadequate response, loss of response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). The implant delivers a small amount of electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under general anesthesia. Half of the subjects will receive active stimulation (the treatment group) and the other half will receive non-active stimulation (the control group). Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety. Blinding will be maintained until the last enrolled and randomized subject in Stage 2 completes Week 12 assessments, and the study database is locked.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

243

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Arizona
      • Mesa, Arizona, Stany Zjednoczone, 85210
        • Arizona Arthritis ans Rheumatology Research, PPLC
      • Phoenix, Arizona, Stany Zjednoczone, 85037
        • Arizona Arthritis Rheumatology & Research, PLLC
      • Tucson, Arizona, Stany Zjednoczone, 85704
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Covina, California, Stany Zjednoczone, 91722
        • Medvin Clinical Research
      • Upland, California, Stany Zjednoczone, 91786
        • Inland Rheumatology Clinical Trials
      • Whittier, California, Stany Zjednoczone, 90602
        • Medvin Clinical Research
    • Colorado
      • Fort Collins, Colorado, Stany Zjednoczone, 80528
        • The Arthritis & Rheumatology Clinic of Northern Colorado
    • Connecticut
      • Stamford, Connecticut, Stany Zjednoczone, 06905
        • Stamford Therapeutics Consortium
    • Delaware
      • Lewes, Delaware, Stany Zjednoczone, 19958
        • Delaware Arthritis
    • Florida
      • Aventura, Florida, Stany Zjednoczone, 33180
        • Arthritis & Rheumatic Disease Specialties
      • Avon Park, Florida, Stany Zjednoczone, 33825
        • HARAC Research Corporation
      • Boynton Beach, Florida, Stany Zjednoczone, 33472
        • RecioMed Clinical Research Network, Inc.
      • Clearwater, Florida, Stany Zjednoczone, 33765
        • Bay Area Rheumatology
      • Plantation, Florida, Stany Zjednoczone, 33324
        • IRIS Research and Development
    • Georgia
      • Augusta, Georgia, Stany Zjednoczone, 30912
        • Augusta University
      • Lawrenceville, Georgia, Stany Zjednoczone, 30044
        • Parris and Associates Rheumatology
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60611
        • Northwestern University
      • Willowbrook, Illinois, Stany Zjednoczone, 60527
        • Willow Rheumatology and Wellness PLLC
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02114
        • Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology
    • Michigan
      • Lansing, Michigan, Stany Zjednoczone, 48910
        • June DO, PC
    • Minnesota
      • Eagan, Minnesota, Stany Zjednoczone, 55121
        • Saint Paul Rheumatology, P.A.
    • Missouri
      • Kansas City, Missouri, Stany Zjednoczone, 64151
        • Kansas City Physician Partners
      • St Louis, Missouri, Stany Zjednoczone, 63122
        • West County Rheumatology
    • Nebraska
      • Lincoln, Nebraska, Stany Zjednoczone, 68516
        • Physician Research Collaboration, LLC
    • New Mexico
      • Albuquerque, New Mexico, Stany Zjednoczone, 87102
        • Albuquerque Center for Rheumatology
    • New York
      • Babylon, New York, Stany Zjednoczone, 11702
        • Long Island Regional Arthritis & Osteoporosis Care
    • North Carolina
      • Charleston, North Carolina, Stany Zjednoczone, 28202
        • Arthritis & Osteoporosis Consultants Of The Carolinas
      • Charlotte, North Carolina, Stany Zjednoczone, 28210
        • DJL Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73103
        • Health Research of Oklahoma, PLLC
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73116
        • Rheumatology Associates of Oklahoma
    • Pennsylvania
      • Allentown, Pennsylvania, Stany Zjednoczone, 18103
        • Lehigh Valley Health Network
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
        • University of Pennsylvania Medical Center
    • Texas
      • Allen, Texas, Stany Zjednoczone, 75013
        • Arthritis & Rheumatology Research Institute, PLLC
      • Austin, Texas, Stany Zjednoczone, 78745
        • Tekton Research
      • Austin, Texas, Stany Zjednoczone, 78717
        • Austin Regional Clinic
      • Austin, Texas, Stany Zjednoczone, 78746
        • Central Texas Rheumatology Associates
      • Colleyville, Texas, Stany Zjednoczone, 76034
        • Precision Comprehensive Clinical Research Solutions
      • Houston, Texas, Stany Zjednoczone, 77043
        • Biopharma Informatic
      • Mesquite, Texas, Stany Zjednoczone, 75150
        • Southwest Rheumatology Research LLC
      • San Antonio, Texas, Stany Zjednoczone, 78229
        • Clinical Trials of Texas, Inc
    • Virginia
      • Fairfax, Virginia, Stany Zjednoczone, 22033
        • Annapolis Rheumatology
    • Washington
      • Bothell, Washington, Stany Zjednoczone, 98021
        • Sound Clinical Research, LLC
    • West Virginia
      • Morgantown, West Virginia, Stany Zjednoczone, 26506
        • West Virginia University

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

22 lata do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • 22-75 years of age at screening
  • Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
  • Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
  • Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12

Exclusion Criteria:

  • Untreated or poorly controlled psychiatric illness or history of substance abuse
  • Significant immunodeficiency due to underlying illness
  • History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
  • Clinically significant cardiovascular disease
  • Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
  • Uncontrolled fibromyalgia
  • History of left or right carotid surgery
  • History of unilateral or bilateral vagotomy, partial or complete splenectomy
  • Recurrent vasovagal syncope episodes
  • Current, regular use of tobacco products
  • Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Treatment

Active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Inne nazwy:
  • Chirurgiczne umieszczenie stymulatora nerwu błędnego wewnątrz szyi

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Inne nazwy:
  • Terapia podstawowa konwencjonalnym syntetycznym DMARD

Active stimulation for 1 min once per day

Pozorny komparator: Control

Non-active stimulation for 1 min once per day

The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.

Inne nazwy:
  • Chirurgiczne umieszczenie stymulatora nerwu błędnego wewnątrz szyi

All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent

Inne nazwy:
  • Terapia podstawowa konwencjonalnym syntetycznym DMARD

Non-active stimulation for 1 min once per day

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
the American College of Rheumatology (ACR) 20 Response
Ramy czasowe: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
DAS28-CRP Good or Moderate Response as Defined by European League Against Rheumatism (EULAR)
Ramy czasowe: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

A subject is considered having a moderate treatment response if:

  • DAS28-CRP score improvement from baseline to Week 12 is > 0.6 and ≤ 1.2, and the DAS28-CRP score at Week 12 is ≤ 5.1; or
  • DAS28-CRP score improvement from baseline to Week 12 is > 1.2, and the DAS28-CRP score at Week 12 is > 3.2.

A subject is considered having a good treatment response if:

• DAS28-CRP score improvement from baseline to Week 12 is > 1.2 and the DAS28-CRP score at Week 12 is ≤ 3.2

Week 12
DAS28-CRP Response (MCID -1.2) at Week 12
Ramy czasowe: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) response is based on the minimal clinically important difference (MCID) of -1.2 from baseline.

DAS28-CRP is based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

Week 12
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22)
Ramy czasowe: Week 12

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 12
ACR20 Response at Week 12 From Day 0
Ramy czasowe: Week 12

Response is defined as achieving at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL).

Week 12

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Bone Erosion Progression, All Completers
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers With Erosive Phenotype
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Bone Erosion Progression, All Completers That Previously Only Failed 1 b/tsDMARD
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:

  • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.
  • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.
  • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.
  • CARLOS (cartilage loss): 25 joints each scored on a scale from 0 (no damage) to 4 (complete ankylosis or fusion), resulting in a total score from 0 to 100.

The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression.

Week 12
Change in Erosion Score, All Completers
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers With Erosive Phenotype
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Erosion Score, All Completers That Previously Only Failed 1 b/tsDMARD
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250.

Week 12
Change in Synovitis Score, All Completers
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers With Erosive Phenotype
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Synovitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24.

Week 12
Change in Osteitis Score, All Completers
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers With Erosive Phenotype
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Change in Osteitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Ramy czasowe: Week 12

RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores:

• Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75.

Week 12
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission
Ramy czasowe: Week 12

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 12
DAS28-CRP Low Disease Activity (LDA) or Remission
Ramy czasowe: Week 12

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 12
the American College of Rheumatology (ACR) 20 Response, All Completers
Ramy czasowe: Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Ramy czasowe: Week 24

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Ramy czasowe: Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Ramy czasowe: Week 24

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Ramy czasowe: Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Ramy czasowe: Week 24

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Ramy czasowe: Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Ramy czasowe: Week 24

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 24
Study Participants That Are Somewhat to Very Satisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Ramy czasowe: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Neither Satisfied Nor Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Ramy czasowe: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Are Somewhat to Very Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Ramy czasowe: Week 24

Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:

  • I am very dissatisfied
  • I am somewhat dissatisfied
  • I am neither satisfied nor dissatisfied
  • I am somewhat satisfied
  • I am very satisfied
Week 24
Study Participants That Would Recommend the SetPoint System to a Family Member or Friend
Ramy czasowe: Week 24

Patients were asked a question about whether they would recommend the SetPoint System to family and friends

Week 24
the American College of Rheumatology (ACR) 20 Response, All Completers
Ramy czasowe: Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Ramy czasowe: Week 36

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Ramy czasowe: Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Ramy czasowe: Week 36

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Ramy czasowe: Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Ramy czasowe: Week 36

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Ramy czasowe: Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Ramy czasowe: Week 36

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 36
the American College of Rheumatology (ACR) 20 Response, All Completers
Ramy czasowe: Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Ramy czasowe: Week 48

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Ramy czasowe: Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Ramy czasowe: Week 48

The CDAI score is based on 4 items:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • EGA, evaluator's global assessment (0=best to 10=worst)

The CDAI score is calculated as follows and ranges from 0 to 76:

• CDAI = TJC28 + SJC28 + SGA + EGA

The CDAI score corresponds to the current RA activity:

  • 0 to ≤ 2.8 Remission
  • >2.8 to ≤ 10 Low disease activity (LDA)
  • >10 to ≤ 22 Moderate disease activity
  • > 22 High disease activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Ramy czasowe: Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Ramy czasowe: Week 48

The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:

  • TJC28, tender joint count of 28 joints (scale 0=best to 28=worst)
  • SJC28, swollen joint count of 28 joints (scale 0=best to 28=worst)
  • SGA, subject global assessment (0=best to 10=worst)
  • hsCRP (mg/L), high sensitivity C-reactive protein concentration (mg/L)

A total score ranges from 0 to 10 and is computed as follows:

DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96

The DAS28-CRP score corresponds to the current RA activity:

  • 0 to < 2.6 Remission
  • 2.6 to < 3.2 LDA
  • 3.2 to ≤ 5.1 Moderate activity
  • > 5.1 High activity
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Ramy czasowe: Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Ramy czasowe: Week 48

HAQ-DI response based on the MCID of -0.22 from baseline.

The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:

  • Dressing and grooming
  • Arising
  • Eating
  • Walking
  • Hygiene
  • Reach
  • Grip
  • Common daily activities

Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:

  • 0 to < 1 Mild difficulties to moderate disability
  • 1 to < 2 Moderate disability
  • 2 to 3 Severe to very severe disability
Week 48
the American College of Rheumatology (ACR) 20 Response, Subjects With 1 Prior b/tsDMARD
Ramy czasowe: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 2 Prior b/tsDMARD
Ramy czasowe: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With 3 Prior b/tsDMARD
Ramy czasowe: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12
the American College of Rheumatology (ACR) 20 Response, Subjects With >=4 Prior b/tsDMARD
Ramy czasowe: Week 12

Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L).

Week 12

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Mark Richardson, MD PhD, Massachusetts General Hospital
  • Główny śledczy: John Tesser, MD, Arizona Arthritis and Rheumatology Research, P.C.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

11 stycznia 2021

Zakończenie podstawowe (Rzeczywisty)

16 maja 2024

Ukończenie studiów (Szacowany)

1 października 2027

Daty rejestracji na studia

Pierwszy przesłany

31 sierpnia 2020

Pierwszy przesłany, który spełnia kryteria kontroli jakości

31 sierpnia 2020

Pierwszy wysłany (Rzeczywisty)

7 września 2020

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

13 listopada 2026

Ostatnia weryfikacja

1 stycznia 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

No sharing data is planned.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Tak

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj